Results 241 to 250 of about 1,425,061 (397)

Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer

JAMA Surgery, 2017
Yuming Jiang, Tuan-jie Li, Xiaoling Liang, Yanfeng Hu, Lei Huang, Z. Liao, Li-ying Zhao, Zhen Han, Shuguang Zhu, M. Wang, Yangwei Xu, Xiaolong Qi, Hao Liu, Yang Yang, Jiang Yu, W. Liu, S. Cai, Guoxin Li   +17 more
semanticscholar   +1 more source

Predictors of disease-free and overall survival in retroperitoneal sarcomas: A modern 16-year multi-institutional study from the United States Sarcoma Collaboration (USSC) [PDF]

, 2019
al., et, Fields, Ryan C., Krasnick, Bradley A.   +2 more
core   +1 more source

Added value of tumor–stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy

I.A. Franken, F. Heilijgers, M.-C.E. Bakker, C. Rubio-Alarcón, F.H. van der Baan, M. Lemmens, P. Delis-van Diemen, M. Sausen, G.A. Meijer, M. Koopman, Vink G.R., RJA Fijneman, W.E. Mesker, J.M.L. Roodhart   +13 more
openalex   +1 more source

Gene expression profiling and immunohistochemistry tests for personalised management of adjuvant chemotherapy decisions in early breast cancer

, 2015
Lorena San Miguel, Joan Vlayen, Chris De Laet   +2 more
openalex   +1 more source

Total Neoadjuvant Therapy for Rectal Cancer: Why Japan Says “Not Yet”

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Total neoadjuvant therapy (TNT) has rapidly gained global acceptance as a standard treatment for locally advanced rectal cancer (LARC). Supported by multiple phase III trials, TNT improves pathological complete response (pCR) rates, enhances systemic control, and expands opportunities for non‐operative management (NOM).
Kay Uehara, Akihisa Matsuda, Takeshi Yamada, Aitsariya Monkhonsupphawan, Hiroshi Yoshida   +4 more
wiley   +1 more source

Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: where do we stand? [PDF]

BMJ Oncol
Yip PL, Lee SF, Chua M.
europepmc   +1 more source

Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial

Ying Chen, Wenxia Li, Jiahua Wu, Genghang Chen, Chun-Min Yang, Hai Lu, Xi Wang, Shusen Wang, Heng Huang, Li Cai, Li Zhao, Roujun Peng, Ying Lin, Jun Tang, Jian Zeng, Lehong Zhang, Yongli Ke, Xianming Wang, Xin-Mei Liu, Anqin Zhang, Fei Xu, Xiwen Bi, Jiajia Huang, Jibin Li, Danmei Pang, Cong Xue, Yanxia Shi, Zhen‐Yu He, Huan‐Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruoxi Hong, Kuikui Jiang, Yong-Yi Zhong, Ge Zhang, Piyawan Tienchaiananda, Masahiro Oikawa, Zhongyu Yuan, Qianjun Chen   +40 more
openalex   +2 more sources

Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T_3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy [PDF]

, 2017
Shi Chen, Li-Ying OuYang, Run‐Cong Nie, Yuanfang Li, Jun Xiang, Zhi-Wei Zhou, Yingbo Chen, Junsheng Peng   +7 more
openalex   +1 more source

Impact of Renin‐Angiotensin System Inhibitors on Renal Function During Temporary Ileostomy Period in Rectal Cancer Patients: A Retrospective Cohort Study

Annals of Gastroenterological Surgery, EarlyView.
This retrospective study explored the potential impact of renin–angiotensin system inhibitors (RASIs) on renal function during the ileostomy period in patients undergoing rectal cancer surgery. RASI use was associated with early postoperative renal impairment, and relatively slow recovery of renal function was observed until stoma closure.
Yusaku Shogen, Ryo Seishima, Masayoshi Monno, Satoru Morita, Kohei Shigeta, Koji Okabayashi, Yuko Kitagawa   +6 more
wiley   +1 more source

Grade-driven adjuvant chemotherapy benefit in high-risk stage IB NSCLC: a retrospective cohort study. [PDF]

J Thorac Dis
Tao H, Lu S, Zhu X, Cong Z, Luo J, Du H, Liu C, Wu H, Shen Y.   +8 more
europepmc   +1 more source